Relatlimab
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Renal Pelvis Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BB |
Pembrolizumab Fred Hutchinson Cancer Center | Phase 3 | BB |
Muamycin UroGen Pharma Ltd. | Phase 3 | B |
Atezolizumab Alliance for Clinical Trials in Oncology | Phase 3 | B |
View all 20 →
Same molecule, other indications
Relatlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →